Mobile-Menu

Vein-to-Vein Process for ATMPs How Integrated Data Flows Improve ATMP Delivery

A guest post by msg industry advisors 4 min Reading Time

Related Vendors

msg industry advisors ag
DÜPERTHAL Sicherheitstechnik GmbH & Co. KG
Frewitt fabrique de machines SA
ProMinent GmbH

Personalized therapies are advancing rapidly, but manufacturing and supply chain often lag behind. This gap affects efficiency, compliance, and patient access. How event-based patient-batch records link handovers, manufacturing activities, and quality data to improve the entire vein-to-vein pathway.

About 20% of the patients die while waiting for their CAR-T cell treatment.(Source: msg industry advisors)
About 20% of the patients die while waiting for their CAR-T cell treatment.
(Source: msg industry advisors)

Advanced Therapy Medicinal Products (ATMPs), including cell and gene therapies, are transforming personalized medicine. Once these patient-specific therapies have been developed and approved, their clinical value depends on a demanding operational condition: they must reach the patient on time, clearly assigned, regulatoryly compliant, and executed under control.

From Breakthrough Science to Operational Reality

According to a 2023 survey of more than 500 manufacturers, 83 % reported having ATMPs in their pipeline. At the same time, commercialization remains at an early stage in “pharma scale” terms: Global spending on cell and gene therapies reached 5.9 billion US dollars in 2023, representing only around 1 % of total global medicine spending.

Related content